Clinical Trial

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The neoadjuvant treatment options commonly used for HR+/HER2- breast cancer are mainly anthracycline sequential or combined with paclitaxel chemotherapy regimens. Several clinical studies have confirmed that albumin paclitaxel is more effective than solvent-based paclitaxel, and therefore, albumin paclitaxel in combination with epirubicin has also become a commonly used chemotherapy regimen in clinical practice. The aim of this study was to explore the efficacy and safety of the Serplulimab combined with nab-paclitaxel and epirubicin in the neoadjuvant treatment of HR+/HER2- breast cancer
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-02.
Status change: Not Yet Recruiting → Recruiting 2025-06-20
Trial Details
NCT Number NCT06860529
Lead Sponsor Henan Cancer Hospital
Conditions HR+/HER2- Breast Cancer
Enrollment 357 participants
Start Date 2025-04-15
Primary Completion 2028-03-31 (estimated)
Study Completion 2030-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-23